Clinical trials: None - Study is to Determine Safety in Healthy Participants
- Condition None - Study is to Determine Safety in Healthy Participants
- Funder type Industry (pharma, biotech, devices)
None - Study is to Determine Safety in Healthy Participants
A Phase I Study to Evaluate LSALT Peptide
A phase I double-blind, placebo-controlled, randomized, single and multiple ascending dose finding study to evaluate the safety and pharmacokinetic profile of LSALT peptide in healthy participants
- Trial name
- NCT03772678
- Testing
- LSALT peptide, 0.9% Saline
- Where
- Australia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Arch Biopartners Inc.